Provide current and high-quality information on the latest developments in the management of lymphoproliferative disease
Create collegial learning opportunities to enable clinicians to share real-world experience and to directly apply new insights to their practice
Foster discussions that allow for the sharing of knowledge and experience among delegates and industry representatives
Respond to emerging professional needs for specific and in-depth information on the latest therapies for lymphoproliferative disease in the Canadian market
Scientific Steering Committee
John Kuruvilla, MD, FRCPC
Peter Anglin, MD, MBA, FRCPC
Conference Agenda
Time
Session
Speaker
7:00 AM
Breakfast (60 mins)
8:00 AM
Introduction & Welcome
Dr. John Kuruvilla & Dr. Peter Anglin
8:10 AM
What is the SOC for POD24 FL
Dr. Dai Chihara MD Anderson Cancer Center
8:30 AM
BiTEs and CARTs in RR-FL
Dr. Ronan Foley McMaster University
8:50 AM
Panel
9:05 AM
Overview of the Treatment of PTCL-NOS
Dr. Matthew Lunning University of Nebraska Medical Center
9:25 AM
Management of Rare PTCL Subtypes
Dr. Anca Prica Princess Margaret Cancer Centre
9:45 AM
Panel
10:00 AM
Health Break (15 mins)
10:15 AM
Evolving Primary Therapy Approaches in DLBCL
Dr. Jason Westin MD Anderson Cancer Center
10:35 AM
What is new in CART for DLBCL
Dr. Jakub Svoboda University of Pennsylvania
10:55 AM
Bispecific Antibodies in RR-DLBCL
Dr. Krish Patel Swedish First Hill Hospital, Seattle, WA
11:15 AM
Panel
11:30 AM
Lunch (60 mins)
12:30 PM
The Shifting Sands of Primary Treatment of Advanced cHL
Dr. Ann LaCasce Dana-Farber Cancer Institute
12:50 PM
Optimizing Treatment of RR-cHL
Dr. Michael Crump Princess Margaret Cancer Centre
1:10 PM
Panel
1:25 PM
The Evolution of Primary Treatment in MCL
Dr. John Kuruvilla Princess Margaret Cancer Centre
1:45 PM
Positioning Novel Therapy in RR-MCL
Dr. Kami Maddocks Ohio State University Comprehensive Cancer Center
2:05 PM
Panel
2:20 PM
Health Break (15 mins)
2:35 PM
CLL Frontline Therapy: Fixed Duration vs. Treat to Progression
Dr. Abi Vijenthira Princess Margaret Cancer Centre
2:55 PM
How to treat CLL after BTKi and BCL2i
Dr. Versha Banerji CancerCare Manitoba
3:15 PM
Richter’s Syndrome: State-of-the-Art Management
Dr. Tanya Siddiqi City of Hope National Medical Center, Duarte, CA
3:30 PM
Panel
3:45 PM
Closing Remarks
Dr. John Kuruvilla & Dr. Peter Anglin
4:00 PM
Dismissal
Our Sponsors
Leaders
Supporters
Canadian Hematology Today provides a forum for the clinical community to share real-world experience and the latest best practices in the treatment and management of hematologic disease.
The journal is published thrice yearly in English and French and is circulated to over 1,100 hematology clinicians and researchers across Canada. It features peer-reviewed articles that present robust clinical perspectives and practical insights into disease management.